Global Gastroenteritis Testing Market – Industry Trends and Forecast to 2031

Análise e tamanho do mercado de testes de gastroenterite

O mercado global de testes de gastroenterite é impulsionado pela crescente prevalência de infeções gastrointestinais em todo o mundo, alimentadas principalmente por agentes patogénicos virais, bacterianos e parasitários. Este crescimento do mercado é ainda impulsionado pela crescente consciencialização sobre a saúde pública e por iniciativas que visam o diagnóstico precoce e a gestão eficaz da gastroenterite. As tecnologias de diagnóstico, como o diagnóstico molecular (PCR), os ensaios de deteção de antigénios e os testes de cultura, desempenham um papel crucial na identificação precisa dos agentes causais da gastroenterite, facilitando o tratamento imediato e reduzindo as taxas de transmissão. Além disso, os avanços nas técnicas de diagnóstico e a integração de plataformas automatizadas melhoram a eficiência e a precisão dos testes, apoiando os prestadores de cuidados de saúde na entrega de resultados de diagnóstico precisos e atempados. Geograficamente, a América do Norte lidera o mercado devido à infraestrutura de cuidados de saúde robusta, aos elevados níveis de sensibilização e aos investimentos significativos em tecnologias de saúde.                                     

O tamanho global do mercado de testes de gastroenterite foi avaliado em 3,99 mil milhões de dólares em 2023 e deverá atingir os 5,90 mil milhões de dólares até 2031, com um CAGR de 5,0% durante o período de previsão de 2024 a 2031. Para além dos insights sobre cenários de mercado, tais como o valor do mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análises especializadas aprofundadas, epidemiologia de pacientes, análise de pipeline, análise de preços e a estrutura regulatória.

Âmbito do relatório e segmentação de mercado       

Definição de mercado

O teste de gastroenterite refere-se a procedimentos de diagnóstico que visam identificar e confirmar a presença de gastroenterite, uma inflamação do trato gastrointestinal normalmente causada por infeções virais, bacterianas ou parasitárias. Estes testes podem envolver vários métodos, como a análise de fezes, o diagnóstico molecular (PCR), ensaios de deteção de antigénios e testes de cultura para detetar agentes patogénicos responsáveis ​​por sintomas de gastroenterite, como diarreia, vómitos, dor abdominal e febre.

Dinâmica do mercado de testes de gastroenterite

Motoristas

• Aumento da prevalência de infeções gastrointestinais  

A crescente incidência de infeções virais, bacterianas e parasitárias que levam à gastroenterite provoca sintomas como diarreia, vómitos, dor abdominal e febre, sendo necessário um diagnóstico preciso e atempado para orientar o tratamento adequado. Por exemplo, de acordo com a National Library of Medicine, os EUA registam mais de 350 milhões de casos de gastroenterite aguda todos os anos, sendo as bactérias de origem alimentar responsáveis ​​por aproximadamente 48 milhões destes casos. A crescente consciencialização entre os prestadores de cuidados de saúde e o público em geral sobre a potencial gravidade e transmissão das infeções gastrointestinais sublinha ainda mais a importância dos testes de diagnóstico na gestão e contenção de surtos. À medida que os sistemas de saúde em todo o mundo dão prioridade à detecção precoce e à contenção de doenças infecciosas , a procura de testes eficientes de gastroenterite continua a crescer e é um factor significativo para a procura de testes de diagnóstico a nível mundial.      

• Avanços nas tecnologias de diagnóstico

Technological advancements in gastroenteritis testing, such as PCR (Polymerase Chain Reaction), antigen detection assays, and automated platforms, play a pivotal role in enhancing the accuracy and efficiency of diagnostic procedures. PCR allows for rapid and specific detection of pathogens, while antigen detection assays offer quick results suitable for point-of-care testing. Automated platforms streamline laboratory workflows, reducing turnaround times and improving diagnostic capabilities. These advancements not only enable healthcare providers to diagnose gastroenteritis more effectively but also contribute to better patient outcomes through prompt initiation of targeted treatments and infection control measures, driving the market growth.

Opportunities

• Technological Innovations and Product Development      

Novel assays incorporating advanced molecular techniques and biomarkers enhance diagnostic sensitivity and specificity, facilitating early and accurate detection of gastrointestinal pathogens. Point-of-care testing devices offer rapid results outside traditional laboratory settings, improving access to diagnostics in remote or resource-limited areas. Multiplex testing platforms enable simultaneous detection of multiple pathogens, optimizing diagnostic efficiency and reducing testing costs. The gastroenteritis testing market presents opportunities for developing novel diagnostic assays, point-of-care testing devices, and multiplex testing platforms.         

• Focus on Preventive Healthcare     

Preventive healthcare initiatives educate populations about the importance of hygiene, vaccination, and early symptom recognition, reducing the incidence and severity of gastrointestinal infections. Early detection through screening programs and routine diagnostic testing allows for timely intervention and treatment, mitigating disease spread and complications. Healthcare providers are increasingly integrating preventive healthcare measures into primary care settings, promoting proactive management of gastrointestinal health and driving the adoption of diagnostic testing for gastroenteritis. The emphasis on preventive healthcare strategies and public health campaigns is boosting the demand for early screening and gastroenteritis tests.

Restraints/Challenges

• High Cost of Diagnostic Tests    

Advanced molecular diagnostics and automated platforms require substantial initial investment in equipment, reagents, and trained personnel, increasing overall healthcare expenditure. This cost-intensive nature limits the affordability and availability of diagnostic testing in underserved populations, hindering timely diagnosis and treatment. The high cost associated with advanced gastroenteritis diagnostic tests poses a significant barrier to accessibility, particularly in resource-constrained settings.     

• Challenges in Pathogen Detection 

Viruses, bacteria, and parasites exhibit diverse genetic profiles and antigenic variability, requiring robust diagnostic assays capable of detecting multiple pathogens simultaneously. The need for accurate pathogen identification is paramount in guiding appropriate treatment decisions and infection control measures. In addition, the emergence of new pathogens and antimicrobial resistance further complicates diagnostic efforts, necessitating continuous research and development in diagnostic technologies. Detecting the wide variability of pathogens responsible for gastroenteritis poses challenges to diagnostic accuracy and efficiency.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In June 2022, Prenetics Group Limited, in collaboration with New Horizon Health, introduced ColoClear by Circle (ColoClear), an innovative, non-invasive at-home screening test for early detection of colorectal cancer. This novel screening test utilizes advanced technology to identify multiple DNA biomarkers and blood cells in human stool   
• In December 2022, Shineco, Inc. obtained approval from the United States Food and Drug Administration (FDA) and a patent from the United States Patent and Trademark Office (US PTO) for its in-situ fecal specimen sampling device designed for stool sample collection. The product features a fingertip swab similar to a massager, a collection tube, and a lid equipped with a unidirectional sampling inlet

Gastroenteritis Testing Market Scope

The market is segmented on the basis of disease strains, product type, testing methods, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Strains

• Bacterial Strains
• Viral Strains
• Parasitic Strains

 Product Type

• Reagent Kits
• Sequencing Kits and Equipment

Testing Methods

• Immunoassay Testing
• Conventional Testing
• Molecular Diagnostic Testing

 End-User

• Hospitals
• Clinics/Medical Centers
• Research Institutes
• Diagnostic Laboratories

Gastroenteritis Testing Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, disease strains, product type, testing methods, and end-user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to heightened public awareness and an increasing demand for advanced diagnostic testing products. The region benefits from a robust healthcare infrastructure and proactive healthcare initiatives, which contribute to early disease detection and management.   

Asia-Pacific is expected to witness significant growth during the forecast period due to rapid technological advancements in diagnostic tools and healthcare systems. The region's expanding healthcare infrastructure, coupled with rising healthcare expenditure and awareness, supports the adoption of advanced gastroenteritis testing methods.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Gastroenteritis Testing Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• BD (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• Hainan Poly Co. Ltd (China)
• WOCKHARDT (India)

SKU-56727